Inflammation and oxidative stress are believed to contribute to
hypertension in
obesity/diabetes. Recently, we reported a role for the AT(2) receptor in blood pressure control in obese Zucker rats. However, the role of AT(2) receptors in
inflammation and oxidative stress in
obesity is not known. Therefore, in the present study, we tested the effects of the AT(2) receptor agonist
CGP-42112A on
inflammation and oxidative stress in obese Zucker rats and compared them in their lean counterparts. Rats were systemically treated with either vehicle (control) or
CGP-42112A (1 μg·kg(-1)·min(-1); osmotic pump) for 2 wk. Markers of
inflammation (CRP, MCP-1, TNF-α, and IL-6) and oxidative stress (HO-1, gp-91(phox)) as well as an
antioxidant (SOD) were determined. Control obese rats had higher plasma levels of CRP, MCP-1, TNF-α,
IL-6, and HO-1 compared with control lean rats. Conversely, plasma SOD activity was lower in control obese than in control lean rats. Furthermore, the
protein levels of TNF-α and gp-91(phox) were higher in the kidney cortex of control obese rats. Interestingly,
CGP-42112A treatment in obese rats reduced the plasma and kidney cortex inflammatory (TNF-α, IL-6) and oxidative stress (gp-91(phox)) markers and increased plasma SOD activity to the levels seen in lean control rats. However,
CGP-42112A treatment in lean rats increased inflammatory (TNF-α, IL-6) and oxidative stress (gp-91(phox)) markers in the plasma and kidney cortex. Our present studies suggest anti-inflammatory and antioxidative functions of AT(2) receptor in obese Zucker rats but proinflammatory and prooxidative functions in lean Zucker rats.